Literature DB >> 19777523

Activators of P-glycoprotein: Structure-activity relationships and investigation of their mode of action.

Katja Sterz1, Lars Möllmann, Anna Jacobs, Dieter Baumert, Michael Wiese.   

Abstract

P-glycoprotein (P-gp), a 170 kDa plasma membrane protein, is one of the most relevant ABC transporters involved in the development of multidrug resistance (MDR). Understanding its mechanism of transport as well as its interactions with various substrates are basic requirements for the development of adequate therapeutic approaches to overcome this kind of resistance against a broad spectrum of structurally unrelated cytostatic drugs. P-gp modulators (activators) that exert various effects on the intracellular accumulation of distinct P-gp substrates are useful tools for investigating the interactions between multiple drug binding sites of this transport protein. In this study, a series of 27 different imidazobenzothiazoles and imidazobenzimidazoles structurally related to the known P-gp activators QB102 and QB11 was designed, and their modulating properties were investigated. Most of them were able to stimulate P-gp-mediated efflux of daunorubicin and rhodamine 123 in a concentration-dependent manner, but some compounds also displayed weak inhibitory effects. Additionally, P-gp-mediated efflux of vinblastine and colchicine was inhibited by several compounds. Therefore, we concluded that the novel compounds bind to the H site of P-gp and activate the efflux of specific substrates of the R site in a positive cooperative manner, whereas binding of H-type substrates is inhibited competitively. This hypothesis is confirmed by the observation that the modulators do not influence hydrolysis of ATP or its affinity toward P-gp.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19777523     DOI: 10.1002/cmdc.200900283

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  10 in total

1.  Multiple ligand docking by Glide: implications for virtual second-site screening.

Authors:  Márton Vass; Ákos Tarcsay; György M Keserű
Journal:  J Comput Aided Mol Des       Date:  2012-05-26       Impact factor: 3.686

2.  Design, Synthesis and Biological Evaluation of Novel HIF1α Inhibitors.

Authors:  Georgina N Masoud; Jin Wang; Jianjun Chen; Duane Miller; Wei Li
Journal:  Anticancer Res       Date:  2015-07       Impact factor: 2.480

3.  A novel non-natural nucleoside that influences P-glycoprotein activity and mediates drug resistance.

Authors:  Kevin T Eng; Anthony J Berdis
Journal:  Biochemistry       Date:  2010-03-02       Impact factor: 3.162

4.  Development of novel rifampicin-derived P-glycoprotein activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrate.

Authors:  Vânia Vilas-Boas; Renata Silva; Andreia Palmeira; Emília Sousa; Luísa Maria Ferreira; Paula Sério Branco; Félix Carvalho; Maria de Lourdes Bastos; Fernando Remião
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

Review 5.  Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.

Authors:  Gergely Szakács; Matthew D Hall; Michael M Gottesman; Ahcène Boumendjel; Remy Kachadourian; Brian J Day; Hélène Baubichon-Cortay; Attilio Di Pietro
Journal:  Chem Rev       Date:  2014-04-23       Impact factor: 60.622

6.  Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.

Authors:  Martin Michaelis; Florian Rothweiler; Nadine Löschmann; Mohsen Sharifi; Taravat Ghafourian; Jindrich Cinatl
Journal:  Oncotarget       Date:  2015-07-10

Review 7.  Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP.

Authors:  Mariline Gameiro; Renata Silva; Carolina Rocha-Pereira; Helena Carmo; Félix Carvalho; Maria de Lourdes Bastos; Fernando Remião
Journal:  Molecules       Date:  2017-04-08       Impact factor: 4.411

Review 8.  The Pharmacology of Xenobiotics after Intracerebro Spinal Fluid Administration: Implications for the Treatment of Brain Tumors.

Authors:  Justine Paris; Eurydice Angeli; Guilhem Bousquet
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 5.923

9.  Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.

Authors:  Martin Michaelis; Florian Rothweiler; Thomas Nerreter; Marijke van Rikxoort; Richard Zehner; Wilhelm G Dirks; Michael Wiese; Jindrich Cinatl
Journal:  BMC Res Notes       Date:  2014-10-10

10.  Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport.

Authors:  Martin Michaelis; Florian Rothweiler; Mario Wurglics; Natália Aniceto; Michaela Dittrich; Heiko Zettl; Michael Wiese; Mark Wass; Taravat Ghafourian; Manfred Schubert-Zsilavecz; Jindrich Cinatl
Journal:  Oncotarget       Date:  2016-03-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.